Finally, a study aimed to identify a novel combination therapy to overcome anti-PD-1 resistance, employing enadenotucirev, a tumor-selective blood-stable adenoviral vector, in combination with nivolumab in patients with advanced/metastatic epithelial cancer. This evidence concerns the gene PDCD1 and neoplasm.